{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.844","value":"5.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.687","value":"0.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Urine samples were collected from participants to assess urine pH levels. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"MEAN","populationDescription":"All Treated Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and until end of treatment (up to 178 weeks)","title":"Part 2 - Changes From Baseline in Urine pH","type":"SECONDARY","unitOfMeasure":"Potential of Hydrogen (pH)"}